Finally, there is evidence suggesting that pharmacological agents used to manage glycaemic control, insulin resistance, and obesity in type 2 diabetes, such as metformin, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2is), may have benefits as adjunctive to insulin therapy in obese PwT1D [6,43,44]. The gene discussed is GLP1R; the disease is obesity disorder.